Last reviewed · How we verify
Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events
The main objective of this project is to evaluate savings in direct costs as regards the use of rivaroxaban versus vitamin K antagonists (VKAs) in routine clinical practice using data from three cohorts of patients receiving VKAs or rivaroxaban in Spain, including the time in therapeutic range (TTR) values of the same and the incidence of events in the first year following diagnosis.
Details
| Lead sponsor | Bayer |
|---|---|
| Status | COMPLETED |
| Enrolment | 249 |
| Start date | Mon Jun 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun May 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Atrial Fibrillation
Interventions
- Rivaroxaban (Xarelto, BAY59-7939)
- Vitamin K antagonists (VKAs)
Countries
Spain